Stockreport

New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN) [Yah...

Novartis AG  (NVS) 
Last novartis ag earnings: 4/28 01:00 am Check Earnings Report
US:NYSE Investor Relations: novartis.com/investors
PDF IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide ; complement activation is a key driver of glomerular [Read more]